ABSTRACT

The management of advanced genitourinary malignancies has undergone a major transformation with the advent of novel drugs and targeted therapies in recent years. Assessment of the treatment risks and benefits is required for each patient and therefore better knowledge of the different clinical and molecular aspects of these diseases is warranted. The results of further studies and biomarker validations are expected to provide more treatment options and improve outcomes in the future management of genitourinary malignancies.

Key words: genitourinary malignancies, renal cell cancer, bladder cancer, prostate cancer, targeted therapies.


The authors have no conflicts of interest to declare.

Correspondence to: Elena Verzoni, MD, Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 1, 20133 Milan, Italy.
Tel +39-02-23903066;
fax +39-02-23902149;
email elena.verzoni@istitutotumori.mi.it